16
Participants
Start Date
October 30, 2018
Primary Completion Date
November 8, 2019
Study Completion Date
November 8, 2019
Lidocaine
0.5 mL (2.5 mg) of lidocaine per injection point will be injected subcutaneously (maximum 10 injection points).
Botulinum toxin type A
0.2 mL of one of three different doses of Dysport per injection point will be injected intradermally (maximum 10 injection points).
Placebo
Part A - 0.5 mL of sodium chloride solution 0.9% (saline solution) per injection point will be injected subcutaneously (maximum 10 injection points).
Placebo
Part B - 0.2 mL of sodium chloride solution 0.9% (saline solution) per injection point will be injected intradermally (maximum 10 injection points, 2,0 mL maximum).
St Pancras Clinical Research, London
Lead Sponsor
Ipsen
INDUSTRY